Peakdale Molecular Scientific Advisory Board

He currently holds the position of CEO at the biotech company SwitchPharma Group plc, and most recently founded the company Numedicus Limited - providing collaborative & consultative services to companies seeking expert advice in the area of novel uses for existing drugs.

Previously David held the positions of CEO at Myotec Therapeutics Ltd (2007-8) and CEO of Arachnova, a company he founded in 1998. Prior to this David was for 10 years Head of Biosciences at Napp Pharma.

David obtained a first degree and PhD at Cambridge University and spent 3 years as a visiting post-doctoral Fellow at the Laboratory of Preclinical Pharmacology at the National Institute of Mental health in Washington DC before joining GSK as a Principal Research Chemist.

In a long career with Roche his roles included Director of Chemistry within Roche UK, and Vice-president Chemistry and Preclinical Sciences at Roche Bioscience, Palo Alto, USA.

Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number of different organisations.

From 2003 to 2007 he was Research Director with Lectus Therapeutics building from start-up a robust drug discovery organisation generating the team, facilities and project portfolio producing the next generation of ion channel modulating medicines.

Whilst at Novartis Terry was the co-inventor on the patents for compounds which have entered clinical development for pain, schizophrenia and anxiety. He also served on the committee responsible for running the Novartis Institute in London and the management of the Nervous System portfolio and was a core member of the Global Discovery Chemistry team, which was responsible for the D2 and D3 activities of over 600 chemists worldwide.

Terry joined Peakdale in August 2005 bringing his extensive experience of pharmaceutical R&D in all phases from early target discovery through to clinical trials, together with his knowledge of leading research teams in many different disease areas, including cardiovascular, oncology, respiratory and nervous system diseases.

Ray is a well known figure in the industry, with over 30 years research experience in synthetic organic chemistry. Ray obtained his PhD in organofluorine chemistry with UMIST and has been named as the inventor on a number of patents.

Paul was most recently Technical Director at BioFocus (now BioFocus DPI, a Galalpagos company) where between 1997 and 2003, he was a founding scientist and Director of Chemistry.

Paul holds a degree in chemistry from New College, Oxford and achieved his D.Phil. at the University of Sussex in 1981. He has previously been Secretary to the UK Peptide and Protein Group and was one of the instigators of the BioMolecular Structure Unit at the University of Sussex.

In June 2009 Paul was appointed Technology Director at Peakdale.

He also played a major role in brokering and managing a number of collaborations with major pharmaceutical and biotechnology companies. While there he directed work on a variety of protease and anti-viral programmes leading to compounds that have moved into clinical development.

Matt has a 1st class honours degree and a PhD from Imperial College London, where he worked with Professor William Motherwell. His post-doctoral research was at the Australian National University with Professor Athel Beckwith and then at Oxford University with Professor Sir Jack Baldwin. Following on from these studies, Matt worked for 7 years at the James Black Foundation, specialising in drugs that modulated G-protein coupled receptors.